The prolonged lockdown of health facilities providing non-urgent gamete cryopreservation -as currently recommended by many reproductive medicine entities and regulatory authorities due to the SARS-CoV-2 pandemic will be detrimental for subgroups of male infertility patients. We believe the existing recommendations should be promptly modified and propose that the same permissive approach for sperm banking granted for men with cancer is expanded to other groups of vulnerable patients. These groups include male infertility patients (e.g., azoospermic men and cryptozoospermic) undergoing medical or surgical treatment to improve sperm quantity and quality, as well as males of reproductive age affected by inflammatory and systemic auto-immune diseases who are about to start treatment with gonadotoxic drugs or who are under remission. In both scenarios, the 'fertility window' may be transitory; postponing diagnostic semen analysis and sperm banking in these men could compromise the prospects of biological parenthood. Moreover, we provide recommendations on how to continue the provision of andrological services in a considered manner and a safe environment. Our opinion is timely and relevant given the fact that fertility services are currently rated as of low priority in most countries.
Andrology. 2020 May 01 [Epub ahead of print]
Sandro C Esteves, Francesco Lombardo, Nicolás Garrido, Juan Alvarez, Armand Zini, Giovanni M Colpi, Jackson Kirkman-Brown, Sheena Em Lewis, Lars Björndahl, Ahmad Majzoub, Chak-Lam Cho, Pedro Vendeira, Jorge Hallak, Edouard Amar, Marcello Cocuzza, Fabiola C Bento, Rita C Figueira, Romualdo Sciorio, Rita J Laursen, Ahmad M Metwalley, Sunil K Jindal, Sijo Parekattil, Ranjith Ramasamy, Carlo Alviggi, Peter Humaidan, John L Yovich, Ashok Agarwal
ANDROFERT, Andrology and Human Reproduction Clinic, Campinas, Brazil., Department of Medical Physiopathology, University of Rome "La Sapienza", Rome, Italy., IVI Foundation, Health Research Institute La Fe, Valencia, Spain., Centro ANDROGEN, La Coruña, Spain., Division of Urology, Department of Surgery, St. Mary's Hospital, McGill University, Montreal, Québec, Canada., Andrology Service, Procrea Swiss Fertility Center, Lugano, Switzerland., Centre for Human Reproductive Science, IMSR, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK., Queens University Belfast, Northern Ireland, United Kingdom., ANOVA, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden., Department of Urology, Hamad Medical Corporation, Doha, Qatar., Department of Surgery, Union Hospital, Hong Kong, Hong Kong., Urology/Andrology Unit, Saúde Atlântica, Clínica do Dragão, Porto, Portugal., Androscience, Science and Innovation Center in Andrology and High-Complex Clinical and Andrology Laboratory, São Paulo, SP, Brazil., Cabinet D'Andrologie Victor Hugo, American Hospital of Paris Reproductive Center, Paris, France., Human Reproduction Center, Division of Urology, University of São Paulo, São Paulo, SP, Brazil., Edinburgh Assisted Conception Programme, EFREC, Royal Infirmary of Edinburgh, Edinburgh, Scotland, UK., Fertility Clinic Skive, Skive Regional Hospital, Skive, Denmark., IVF laboratory, Al Saad Specialist Hospitals, Jeddah, KSA, Saudi Arabia., Division of Reproductive Medicine and Andrology, Jindal Hospital, Meerut, UP, India., PUR Clinic and University of Central Florida, Clermont, FL, USA., Department of Urology, Miller School of Medicine, University of Miami, Miami, Florida, USA., Department of Neuroscience, Reproductive Science and Odontostomatology, University of Naples Federico II, Naples, Italy., Faculty of Health, Aarhus University, Aarhus, Denmark., PIVET Medical Centre, Perth, Australia., Andrology Center, Department of Urology, Cleveland Clinic, Cleveland, Ohio, USA.